Methods of using compounds as neuro-protective agents

A method of treating a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, amytrophic lateral sclerosis or cerebral trauma in a mammal in need of such treatment which comprises administering to said mammal a lipid peroxidation inhibitory amount of a compound of formula (II)

• wherein:
• Ar is phenyl, pyridyl, or tetrahydronaphthyl substituted with zero to two substituents selected from the group consisting of —(C1-C6)alkyl, hydroxy and halo;
• and substituted with one or two substituents selected from the group consisting of —O(CH2)tR6,
• and —(C1-C6 alkyl)R6;
• provided that the phenyl or pyridyl group of Ar may additionally be substituted with two substituents which when taken together with the carbon atoms to which they are attached form a phenyl ring;
• where R6 is —NR7R8, morpholin-1l-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl or piperazin-1-yl substituted with —(C1-C4)alkyl or
• and R7 and R8 are each individually hydrogen, —(C1-C6)alkyl, —(CH2)pOH, —(CH2)p-piperidyl, —(CH2)pS(C1-C6)alkyl or
• represents a double or single bond;
• X is —O— or —S—;
• Y is —CHR5—, —O— or —S—;
• R is H or —(C1-C6)alkyl;
• R1 and R2 are each individually —(C1-C6)alkyl or —(C1-C6)alkoxy;
• R3 is H or —(C1-C6)alkyl;
• R4 is hydrogen, or when Y is —CHR5, R4 and R5 are each individually H or when taken together form a bond;
• m is an integer from 0 to 2, both inclusive;
• q is 0 or 1;
• n is an integer from 0 to 4 both inclusive;
• p is an integer from 1 to 6 both inclusive;
• and
• t is an integer from 1 to 4 both inclusive;
• or a pharmaceutically acceptable salt, hydrate or optical isomer thereof.

A method of treating a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, amytrophic lateral sclerosis or cerebral trauma in a mammal in need of such treatment which comprises administering to said mammal a lipid peroxidation inhibitory amount of a compound of formula (I)

• wherein
• Ar is phenyl or pyridyl substituted With zero to two substituents selected from the group consisting of —(C1-C6) alkyl, hydroxy and halo;
• and substituted with one or two substituents selected from the group consisting of
• and —(C1-C6) alkyl R6;
• provided that the phenyl or pyridyl group of Ar may additionally be substituted with two substituents which when taken together with the carbon atoms to which they are attached form a phenyl ring;
• where R6 is —NR7R8, morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl or piperazin-1-yl substituted with —(C1-C4)alkyl or
• and R7 and R8 are each individually hydrogen, —(C1-C6) alkyl, —(CH2)pOH or —(CH2)ppiperidyl;
• X is —O— or —S—;
• Y is —CHR5—, —O— or —S—;
• R is —H or —(C1-C6)alkyl;
• R1 and R2 are each individually —(C1-C6)alkyl;
• R3 is H or —(C1-C6)alkyl;
• R4 is hydrogen, or when Y is —CHR5, R4 and R5 are each individually H or when taken together form a bond;
• m is 0 or 1;
• n is an integer from 0 to 4 both inclusive;
• and
• p is an integer from 1 to 6 both inclusive;
• or a pharmaceutically acceptable salt, hydrate or optical isomer thereof.